Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Upgraded to Hold at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC – Free Report) to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Frazier Life Sciences Acquisition Corp. II Price Performance

NASDAQ:FLSC opened at $10.30 on Friday. Frazier Life Sciences Acquisition Corp. II has a 1-year low of $10.18 and a 1-year high of $10.63.

Insiders Place Their Bets

In related news, CEO Albert Cha bought 300,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was bought at an average cost of $10.00 per share, with a total value of $3,000,000.00. Following the completion of the acquisition, the chief executive officer owned 300,000 shares in the company, valued at approximately $3,000,000. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Frazier Life Sciences Acquisition Corp. II Company Profile

(Get Free Report)

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.

Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company’s objective is to provide a publicly traded platform for a private life sciences business through a business combination.

Frazier Life Sciences Acquisition Corp.

Further Reading